LEVI-04
Pain due to Osteoarthritis of the Knee
Phase 2Active
Key Facts
About Levicept
Levicept is a private, clinical-stage biotech developing LEVI-04, a novel p75NTR-Fc fusion protein that inhibits neurotrophin-3 to treat chronic pain. The drug has successfully completed a Phase II trial in osteoarthritis knee pain, meeting all endpoints with a favorable safety profile, notably showing no rapid joint deterioration—a key differentiator from anti-NGF therapies. Backed by experienced leadership and venture capital from Medicxi, the company is positioned to advance its lead program into later-stage development and explore expansion into other pain indications.
View full company profile